Tesaro Inc., of Waltham, Mass., reported net product revenue of $50.2 million for the first quarter of 2018, which included Zejula (niraparib), a PARP inhibitor approved for maintenance therapy in ovarian cancer, sales of $48.9 million, compared to $2.1 million for the first quarter of 2017.